BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29950222)

  • 1. [Application of Chimeric Antigen Receptor-Modified NK Cells in Multiple Myeloma].
    Wei HP; Yang N; Gu ZY; Zhao SS; Wang FY; Luo L; Guan LX; Gao CJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):796-801. PubMed ID: 29950222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
    Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.
    Jiang H; Zhang W; Shang P; Zhang H; Fu W; Ye F; Zeng T; Huang H; Zhang X; Sun W; Man-Yuen Sze D; Yi Q; Hou J
    Mol Oncol; 2014 Mar; 8(2):297-310. PubMed ID: 24388357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death.
    Wu L; Liu F; Yin L; Wang F; Shi H; Zhao Q; Yang F; Chen D; Dong X; Gu Y; Xing N
    Cancer Commun (Lond); 2022 Aug; 42(8):768-783. PubMed ID: 35706368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application of Chimeric Antigen Receptor-Modified CAR-T/NK Cells to Treatment of Multiple Myeloma].
    Wang L; Ou jF; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):568-72. PubMed ID: 25948226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma].
    Min JT; Zhang L; Long CR; Fan HL; Li ZZ
    Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):322-329. PubMed ID: 37078213
    [No Abstract]   [Full Text] [Related]  

  • 7. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
    Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
    Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
    [No Abstract]   [Full Text] [Related]  

  • 8. [Establishment of chimeric antigen receptor NK92MI cells recognizing HBsAg].
    Dong S; Huang M; Li D; Gao Y; Li Z; Liu C
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Sep; 37(9):788-793. PubMed ID: 34533125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Construction of ROR1 Targeting Chimeric Antigen Receptor Modified T Cells and Its Killing Effect for ROR1-positive Tumor Cells].
    Chen Y; Mo ZM; Qin DY; Guo FC; Liao XL; Hu M; Chen Q; Wang YS
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 50(2):145-151. PubMed ID: 31106530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines.
    Kulemzin SV; Matvienko DA; Sabirov AH; Sokratyan AM; Chernikova DS; Belovezhets TN; Chikaev AN; Taranin AV; Gorchakov AA
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):44. PubMed ID: 30871576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
    Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K; He X; Devine SM; Zhang X; Caligiuri MA; Hofmeister CC; Yu J
    Leukemia; 2014 Apr; 28(4):917-27. PubMed ID: 24067492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Killing effect of Robo1 targeted Chimeric Antigen Receptor modified NK92 cells against glioma and neuroblastoma cells].
    Qu Y; Bi JZ
    Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(11):860-866. PubMed ID: 29609271
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
    An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
    Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
    Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
    Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Functional investigation of chimeric antigen receptor T cells targeting LMP1 antigen].
    He HZ; Xing YY; Zhang Y; Xu YX; Tian Z; Xing HY; Tang KJ; Rao Q; Wang JX; Wang M
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):229-234. PubMed ID: 35405781
    [No Abstract]   [Full Text] [Related]  

  • 16. [Killing Effect of A CD7 Chimeric Antigen Receptor-Modified NK-92MI Cell Line on CD7-Positive Hematological Malignant Cells].
    Zhu XY; Liu X; Wang XB; Wang AY; Wang M; Liu NN; You FT; Pan GF; Yang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1367-1375. PubMed ID: 32798428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.
    Klapdor R; Wang S; Morgan M; Dörk T; Hacker U; Hillemanns P; Büning H; Schambach A
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.
    Romanski A; Uherek C; Bug G; Seifried E; Klingemann H; Wels WS; Ottmann OG; Tonn T
    J Cell Mol Med; 2016 Jul; 20(7):1287-94. PubMed ID: 27008316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.
    Zhang Q; Tian K; Xu J; Zhang H; Li L; Fu Q; Chai D; Li H; Zheng J
    J Immunol Res; 2017; 2017():6915912. PubMed ID: 29423418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.